{"id":391438,"date":"2015-03-25T00:00:00","date_gmt":"2015-03-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforeu0815-biopharma-novel-oral-anticoagulants-for-acute-coronary-syndrome-atrial-fibrillation-and-venous\/"},"modified":"2026-03-31T09:04:02","modified_gmt":"2026-03-31T09:04:02","slug":"pforeu0815-biopharma-novel-oral-anticoagulants-for-acute-coronary-syndrome-atrial-fibrillation-and-venous","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforeu0815-biopharma-novel-oral-anticoagulants-for-acute-coronary-syndrome-atrial-fibrillation-and-venous\/","title":{"rendered":"Novel Oral Anticoagulants for Acute Coronary Syndrome, Atrial Fibrillation, and Venous Thromboembolism in the EU5  | Physician &#038; Payer Forum | EU5 | 2015"},"content":{"rendered":"<p><em>How Are Payer Policies and Physician Preferences Shaping the Prescribing Landscape?<\/em><\/p>\n<p>The European oral anticoagulation market has undergone a dramatic expansion in the treatment armamentarium in recent years, with the emergence of the novel oral anticoagulants (NOACs) and their approval for use in a range of indications. While the NOACs offer certain clinical and dosing advantages over the traditional mainstays of oral anticoagulation\u2014the vitamin K antagonists (VKAs)\u2014their relatively high cost means that the increasingly cost-conscious European markets have sought to impose certain restrictions on the use of these agents.<\/p>\n","protected":false},"template":"","class_list":["post-391438","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-coronary-syndrome","biopharma-therapy-areas-atrial-fibrillation","biopharma-therapy-areas-cardiovascular","biopharma-therapy-areas-venous-thromboembolism","biopharma-geography-us","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391438\/revisions"}],"predecessor-version":[{"id":576973,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391438\/revisions\/576973"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}